{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:23:09Z","timestamp":1787923389246,"version":"build-2784847793"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Henan Province Science and Technology Research and Development","award":["232102311068"],"award-info":[{"award-number":["232102311068"]}]},{"name":"Henan Provincial Medical Science and Technology Research Joint Venture","award":["SBGJ202403038"],"award-info":[{"award-number":["SBGJ202403038"]}]},{"name":"This work was supported by Henan Province Science and Technology Research and Development","award":["242102311176"],"award-info":[{"award-number":["242102311176"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Proced Online"],"DOI":"10.1186\/s12575-025-00274-5","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:02:39Z","timestamp":1747731759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Heterogeneity and efficacy of immunotherapy in multiple cancer: insights from a meta-analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Weidong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengya","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongliang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"274_CR1","doi-asserted-by":"publisher","unstructured":"Bao Y. Study on the efficacy and safety of BCMA-targeted CAR-T in the treatment of relapsed\/refractory multiple myeloma. Beijing: Tongfang Knowledge Network (Beijing) Technology Co., Ltd.; 2023. https:\/\/doi.org\/10.27438\/d.cnki.gyadu.2022.000460.","DOI":"10.27438\/d.cnki.gyadu.2022.000460"},{"issue":"1","key":"274_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/raon-2022-0002","volume":"56","author":"U Bezeljak","year":"2022","unstructured":"Bezeljak U. Cancer gene therapy goes viral: viral vector platforms come of age. Radiol Oncol. 2022;56(1):1\u201313. https:\/\/doi.org\/10.2478\/raon-2022-0002.","journal-title":"Radiol Oncol"},{"key":"274_CR3","doi-asserted-by":"publisher","unstructured":"Blumenschein GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman MJ, Heymach JV, Govindan R, Bachier C, Doger DSB, Matthew JF, Olszanski AJ, Vincent KL, Hyland N, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou D, Pentony MM, Sanderson JP, Gerry A, Marks D, Bai J, Holdich T, Norry E, Fracasso PM. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGEA10+ advanced non-small cell lung cancer. J ImmunoTherap Cancer. 2022;10(1):e003581. https:\/\/doi.org\/10.1136\/jitc-2021-003581.","DOI":"10.1136\/jitc-2021-003581"},{"issue":"3","key":"274_CR4","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","volume":"8","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Natrakul DA, Karrs J, Patel N, Maass-Moreno R, Ahlman MA, Mikkilineni L, Mann J, Stroncek DF, Highfill SL, Fromm GC, Patel R, Pittaluga S, Kochenderfer JN. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Adv. 2024;8(3):802\u201314. https:\/\/doi.org\/10.1182\/bloodadvances.2023011470.","journal-title":"Blood Adv."},{"issue":"12","key":"274_CR5","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jclinepi.2008.12.010","volume":"62","author":"D Chambers","year":"2009","unstructured":"Chambers D, Rodgers M, Woolacott N. Not only randomized controlled trials, but also case series should be considered in systematic reviews of rapidly developing technologies. J Clin Epidemiol. 2009;62(12):1253-1260 e1254. https:\/\/doi.org\/10.1016\/j.jclinepi.2008.12.010.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"274_CR6","doi-asserted-by":"publisher","first-page":"5242","DOI":"10.1128\/Jvi.03819-13","volume":"88","author":"MC Claudepierre","year":"2014","unstructured":"Claudepierre MC, Hortelano J, Schaedler E, Kleinpeter P, Geist M, Remy-Ziller C, Brandely R, Tosch C, Laruelle L, Jawhari A, Menguy T, Marchand JB, Romby P, Schultz P, Hartmann G, Rooke R, Bonnefoy JY, Preville X, Rittner K. Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy. J Virol. 2014;88(10):5242\u201355. https:\/\/doi.org\/10.1128\/Jvi.03819-13.","journal-title":"J Virol"},{"issue":"1","key":"274_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","volume":"13","author":"M Conroy","year":"2022","unstructured":"Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun. 2022;13(1):392. https:\/\/doi.org\/10.1038\/s41467-022-27960-2.","journal-title":"Nat Commun"},{"issue":"5","key":"274_CR8","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1002\/cam4.3753","volume":"10","author":"T Curran","year":"2021","unstructured":"Curran T, Sun ZQ, Gerry B, Findlay VJ, Wallace K, Li ZH, Paulos C, Ford M, Rubinstein MP, Chung DJ, Camp ER. Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities. Cancer Med. 2021;10(5):1805\u201314. https:\/\/doi.org\/10.1002\/cam4.3753.","journal-title":"Cancer Med"},{"issue":"S1","key":"274_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","volume":"94","author":"S Feins","year":"2019","unstructured":"Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3\u20139. https:\/\/doi.org\/10.1002\/ajh.25418.","journal-title":"Am J Hematol"},{"issue":"6","key":"274_CR10","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/cancers13061383","volume":"13","author":"PF Ferrucci","year":"2021","unstructured":"Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene Laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers. 2021;13(6):1383. https:\/\/doi.org\/10.3390\/cancers13061383.","journal-title":"Cancers"},{"issue":"5","key":"274_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.19.01892","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 2020;38(5):415\u201322. https:\/\/doi.org\/10.1200\/JCO.19.01892. Epub 2019 Dec 9.","journal-title":"J Clin Oncol."},{"issue":"1","key":"274_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"274_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-020-00953-8","volume":"13","author":"R Gu","year":"2020","unstructured":"Gu R, Liu F, Zou D, Xu Y, Lu Y, Liu B, Liu W, Chen X, Liu K, Guo Y, Gong X, Lv R, Chen X, Zhou C, Zhong M, Wang H, Wei H, Mi Y, Qiu L, Lv L, Wang M, Wang Y, Zhu X, Wang J. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):122. https:\/\/doi.org\/10.1186\/s13045-020-00953-8.","journal-title":"J Hematol Oncol."},{"issue":"2","key":"274_CR14","doi-asserted-by":"publisher","first-page":"e180416","DOI":"10.1001\/jamanetworkopen.2018.0416","volume":"1","author":"B Gyawali","year":"2018","unstructured":"Gyawali B, Hey SP, Kesselheim AS. A comparison of response patterns for progression-free survival and overall survival following treatment for cancer with PD-1 inhibitors: a meta-analysis of correlation and differences in effect sizes. Jama Netw Open. 2018;1(2):e180416. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.0416.","journal-title":"Jama Netw Open"},{"issue":"2","key":"274_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, Gagliato DD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154\u201373. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.001.","journal-title":"Cancer Cell"},{"issue":"10","key":"274_CR16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/ajh.25582","volume":"94","author":"H Jiang","year":"2019","unstructured":"Jiang H, Li C, Yin P, Guo T, Liu L, Xia L, Wu Y, Zhou F, Ai L, Shi W, Lu X, Wang H, Tang L, Wei Q, Deng J, Jin R, Xiong W, Dong J, Mei H, Hu Y. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. Am J Hematol. 2019;94(10):1113\u201322. https:\/\/doi.org\/10.1002\/ajh.25582. Epub 2019 Aug 2.","journal-title":"Am J Hematol."},{"issue":"1","key":"274_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, Li F, Xie D, Xiong X, Wang J, Lu W, Zhang H, Zhao M. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15(1):88. https:\/\/doi.org\/10.1186\/s13045-022-01308-1.","journal-title":"J Hematol Oncol."},{"issue":"24","key":"274_CR18","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.3390\/cancers13246231","volume":"13","author":"RL Johnson","year":"2021","unstructured":"Johnson RL, Cummings M, Thangavelu A, Theophilou G, de Jong D, Orsi NM. Barriers to immunotherapy in ovarian cancer: metabolic, genomic, and immune perturbations in the tumour microenvironment. Cancers. 2021;13(24):6231. https:\/\/doi.org\/10.3390\/cancers13246231.","journal-title":"Cancers"},{"issue":"10","key":"274_CR19","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.3390\/cancers15102721","volume":"15","author":"M Kciuk","year":"2023","unstructured":"Kciuk M, Yahya EB, Mohamed MMI, Rashid S, Iqbal MO, Kontek R, Abdulsamad MA, Allaq AA. Recent advances in molecular mechanisms of cancer immunotherapy. Cancers. 2023;15(10):2721. https:\/\/doi.org\/10.3390\/cancers15102721.","journal-title":"Cancers"},{"issue":"7","key":"274_CR20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1001\/archgenpsychiatry.2011.2112","volume":"69","author":"KS Kendler","year":"2012","unstructured":"Kendler KS, Sundquist K, Ohlsson H, Palm\u00e9r K, Maes H, Winkleby MA, Sundquist J. Genetic and familial environmental influences on the risk for drug abuse. Arch Gen Psychiatry. 2012;69(7):690\u20137. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.2112.","journal-title":"Arch Gen Psychiatry"},{"key":"274_CR21","doi-asserted-by":"publisher","unstructured":"Kumar M, Thangavel C, Becker RC, Sadayappan S. Monoclonal antibody-based immunotherapy and its role in the development of cardiac toxicity. Cancers (Basel). 2020;13(1). https:\/\/doi.org\/10.3390\/cancers13010086.","DOI":"10.3390\/cancers13010086"},{"issue":"1","key":"274_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40. https:\/\/doi.org\/10.1186\/s12943-023-01740-y.","journal-title":"Mol Cancer"},{"issue":"15","key":"274_CR23","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.3390\/cancers14153575","volume":"14","author":"YF Lao","year":"2022","unstructured":"Lao YF, Shen DM, Zhang WL, He R, Jiang M. Immune checkpoint inhibitors in cancer therapy-how to overcome drug resistance? Cancers. 2022;14(15):3575. https:\/\/doi.org\/10.3390\/cancers14153575.","journal-title":"Cancers"},{"issue":"22","key":"274_CR24","doi-asserted-by":"publisher","first-page":"6990","DOI":"10.1182\/bloodadvances.2023011399","volume":"7","author":"EC Liang","year":"2023","unstructured":"Liang EC, Albittar A, Huang JJ, Hirayama AV, Kimble EL, Portuguese AJ, Chapuis A, Shadman M, Till BG, Cassaday RD, Milano F, Kiem HP, Riddell SR, Turtle CJ, Maloney DG, Gauthier J. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed\/refractory CLL. Blood Adv. 2023;7(22):6990\u20137005. https:\/\/doi.org\/10.1182\/bloodadvances.2023011399.","journal-title":"Blood Adv."},{"key":"274_CR25","doi-asserted-by":"publisher","unstructured":"Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C, Wang D, Wang J, Jiang L, Xu H, Xu J, Zhou X, Hong Z, Wang N, Huang L, Zhang S, Chen L, Mao X, Xiao M, Zhang W, Meng L, Cao Y, Zhang T, Li J, Zhou J. A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med. 2021;11(3):e346. https:\/\/doi.org\/10.1002\/ctm2.346.","DOI":"10.1002\/ctm2.346"},{"issue":"9","key":"274_CR26","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, Petrocca F, Yeri A, Finney O, Caia A, Yang Z, Martin N, Campbell TB, Rytlewski J, Fuller J, Hege K, Munshi NC, Kochenderfer JN. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286\u201394. https:\/\/doi.org\/10.1038\/s41591-023-02496-0. Epub 2023 Aug 17.","journal-title":"Nat Med."},{"key":"274_CR27","doi-asserted-by":"publisher","first-page":"989989","DOI":"10.3389\/fnut.2022.989989","volume":"9","author":"C Liu","year":"2022","unstructured":"Liu C, Yu Y, Wang G, Liu JY, Liu RJ, Liu LJ, Yang XX, Li HY, Gao CD, Lu Y, Zhuang J. From tumor mutational burden to characteristic targets analysis: identifying the predictive biomarkers and natural product interventions in cancer management. Front Nutr. 2022;9:989989. https:\/\/doi.org\/10.3389\/fnut.2022.989989.","journal-title":"Front Nutr"},{"issue":"6","key":"274_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ajh.26160","volume":"96","author":"S Liu","year":"2021","unstructured":"Liu S, Deng B, Yin Z, Lin Y, An L, Liu D, Pan J, Yu X, Chen B, Wu T, Chang AH, Tong C. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol. 2021;96(6):671\u20139. https:\/\/doi.org\/10.1002\/ajh.26160. Epub 2021 Mar 29.","journal-title":"Am J Hematol."},{"issue":"4","key":"274_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/blood.2021014498","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, Wang L, Wang Q, Jin D, Li J, Huang X. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140(4):321\u201334. https:\/\/doi.org\/10.1182\/blood.2021014498.","journal-title":"Blood."},{"key":"274_CR30","doi-asserted-by":"publisher","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D, Senechal B, Bermudez VP, Purdon TJ, Hosszu K, McAvoy DP, Farzana T, Mead E, Wilcox JA, Santomasso BD, Shah GL, Shah UA, Korde N, Lesokhin A, Tan CR, Hultcrantz M, Hassoun H, Roshal M, Sen F, Dogan A, Landgren O, Giralt SA, Park JH, Usmani SZ, Rivi\u00e8re I, Brentjens RJ, Smith EL. GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med. 2022;387(13):1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2209900.","DOI":"10.1056\/NEJMoa2209900"},{"issue":"43","key":"274_CR31","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846\u201361. https:\/\/doi.org\/10.3748\/wjg.v24.i43.4846.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"274_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, Guo T, Kou H, Liu L, Tang L, Yin P, Wang Z, Ai L, Ke S, Xia Y, Deng J, Chen L, Cai L, Sun C, Xia L, Hua G, Hu Y. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14(1):161. https:\/\/doi.org\/10.1186\/s13045-021-01170-7.","journal-title":"J Hematol Oncol."},{"issue":"7378","key":"274_CR33","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480\u20139. https:\/\/doi.org\/10.1038\/nature10673.","journal-title":"Nature"},{"issue":"12","key":"274_CR34","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/S1470-2045(24)00528-X","volume":"25","author":"S Miller","year":"2024","unstructured":"Miller S, Jiang R, Schipper M, Fritsche LG, Strohbehn G, Wallace B, Brinzevich D, Falvello V, McMahon BH, Zamora-Resendiz R. Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study. Lancet Oncol. 2024;25(12):1666\u201376.","journal-title":"Lancet Oncol"},{"key":"274_CR35","doi-asserted-by":"publisher","unstructured":"Morgado M, Placido A, Morgado S, Roque F. Management of the adverse effects of immune checkpoint inhibitors. Vaccines (Basel). 2020;8(4). https:\/\/doi.org\/10.3390\/vaccines8040575.","DOI":"10.3390\/vaccines8040575"},{"issue":"6","key":"274_CR36","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/cncr.30430","volume":"123","author":"EA Mroz","year":"2017","unstructured":"Mroz EA, Rocco JW. The challenges of tumor genetic diversity. Cancer. 2017;123(6):917\u201327. https:\/\/doi.org\/10.1002\/cncr.30430.","journal-title":"Cancer"},{"issue":"1","key":"274_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12939-023-01962-y","volume":"22","author":"O Omotoso","year":"2023","unstructured":"Omotoso O, Teibo JO, Atiba FA, Oladimeji T, Paimo OK, Ataya FS, Batiha GE, Alexiou A. Addressing cancer care inequities in sub-Saharan Africa: current challenges and proposed solutions. Int J Equity Health. 2023;22(1):189. https:\/\/doi.org\/10.1186\/s12939-023-01962-y.","journal-title":"Int J Equity Health"},{"issue":"30","key":"274_CR38","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human. Phase I Trial J Clin Oncol. 2021;39(30):3340\u201351. https:\/\/doi.org\/10.1200\/JCO.21.00389. Epub 2021 Jul 29.","journal-title":"Phase I Trial. J Clin Oncol."},{"issue":"11","key":"274_CR39","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","volume":"24","author":"J Pan","year":"2023","unstructured":"Pan J, Tang K, Luo Y, Seery S, Tan Y, Deng B, Liu F, Xu X, Ling Z, Song W, Xu J, Duan J, Wang Z, Li C, Wang K, Zhang Y, Yu X, Zheng Q, Zhao L, Zhang J, Chang AH, Feng X. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2023;24(11):1229\u201341. https:\/\/doi.org\/10.1016\/S1470-2045(23)00436-9. Epub 2023 Oct 17.","journal-title":"Lancet Oncol."},{"issue":"23","key":"274_CR40","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood.2021013733","volume":"139","author":"Y Qi","year":"2022","unstructured":"Qi Y, Zhao M, Hu Y, Wang Y, Li P, Cao J, Shi M, Tan J, Zhang M, Xiao X, Xia J, Ma S, Qiao J, Yan Z, Li H, Pan B, Sang W, Li D, Li Z, Zhou J, Huang H, Liang A, Zheng J, Xu K. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood. 2022;139(23):3376\u201386. https:\/\/doi.org\/10.1182\/blood.2021013733.","journal-title":"Blood."},{"key":"274_CR41","doi-asserted-by":"publisher","unstructured":"Qu X, An G, Sui W, Wang T, Zhang X, Yang J, Zhang Y, Zhang L, Zhu D, Huang J, Zhu S, Yao X, Li J, Zheng C, Zhu K, Wei Y, Lv X, Lan L, Yao Y, Zhou D, Lu P, Qiu L, Li J. Phase 1 study of C-CAR088 a novel humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma. J ImmunoTherap Cancer. 2022;10(9):e005145. https:\/\/doi.org\/10.1136\/jitc-2022-005145.","DOI":"10.1136\/jitc-2022-005145"},{"key":"274_CR42","doi-asserted-by":"publisher","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RS, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, James NK. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.\u00a0N Engl J Med. 2019;380(18):1726-37. https:\/\/doi.org\/10.1056\/NEJMoa1817226.","DOI":"10.1056\/NEJMoa1817226"},{"key":"274_CR43","doi-asserted-by":"publisher","unstructured":"Shi X, Yan L, Shang J, Kang L, Yan Z, Jin S, Zhu M, Chang H, Gong F, Zhou J, Chen G, Pan J, Liu D, Zhu X, Tang F, Liu M, Liu W, Yao F, Yu L, Wu D, Fu C. Anti CD19 and anti\u2010BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem\u2010cell transplantation for high\u2010risk newly diagnosed multiple myeloma. Abstr Am J Hematol. 2022;97(5):537-47. https:\/\/doi.org\/10.1002\/ajh.v97.510.1002\/ajh.26486.","DOI":"10.1002\/ajh.v97.510.1002\/ajh.26486"},{"issue":"5","key":"274_CR44","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O\u2019Byrne K, Kulasinghe A. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044\u201360. https:\/\/doi.org\/10.3390\/curroncol29050247.","journal-title":"Curr Oncol"},{"issue":"9","key":"274_CR45","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies(): development and validation of a new instrument. Anz J Surg. 2003;73(9):712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"Anz J Surg"},{"issue":"11","key":"274_CR46","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver N, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia. 2021;35(11):3282\u20136. https:\/\/doi.org\/10.1038\/s41375-021-01232-2. Epub 2021 Apr 8.","journal-title":"Leukemia."},{"issue":"1","key":"274_CR47","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","volume":"8","author":"L Tang","year":"2023","unstructured":"Tang L, Huang Z, Mei H, Hu Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Ther. 2023;8(1):306. https:\/\/doi.org\/10.1038\/s41392-023-01521-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"274_CR48","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/sj.gt.3301392","volume":"8","author":"M Toda","year":"2001","unstructured":"Toda M, Martuza RL, Rabkin SD. Combination suicide\/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther. 2001;8(4):332\u20139. https:\/\/doi.org\/10.1038\/sj.gt.3301392.","journal-title":"Gene Ther"},{"issue":"8","key":"274_CR49","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/vaccines11081357","volume":"11","author":"A Tojjari","year":"2023","unstructured":"Tojjari A, Saeed A, Singh M, Cavalcante L, Sahin IH, Saeed A. A comprehensive review on cancer vaccines and vaccine strategies in hepatocellular carcinoma. Vaccines. 2023;11(8):1357. https:\/\/doi.org\/10.3390\/vaccines11081357.","journal-title":"Vaccines"},{"key":"274_CR50","doi-asserted-by":"publisher","unstructured":"Uscanga-Palomeque AC, Chavez-Escamilla AK, Alvizo-Baez CA, Saavedra-Alonso S, Terrazas-Armendariz LD, Tamez-Guerra RS, Rodriguez-Padilla C, Alcocer-Gonzalez JM. CAR-T cell therapy: from the shop to cancer therapy. Int J Mol Sci. 2023;24(21). https:\/\/doi.org\/10.3390\/ijms242115688.","DOI":"10.3390\/ijms242115688"},{"key":"274_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","volume":"6","author":"SM Vareki","year":"2018","unstructured":"Vareki SM. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6:157. https:\/\/doi.org\/10.1186\/s40425-018-0479-7.","journal-title":"J Immunother Cancer"},{"key":"274_CR52","doi-asserted-by":"publisher","unstructured":"Wang CM, et al. Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.\u00a0Abstr\u00a0Clin Cancer Res. 2017;23(5):1156\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1365.","DOI":"10.1158\/1078-0432.CCR-16-1365"},{"key":"274_CR53","doi-asserted-by":"publisher","unstructured":"Wang Q. A single-center, open, single-arm clinical study on the safety and efficacy of infusion of Anti-BCMA CAR-T in the treatment of relapsed\/refractory\/high-risk BCMA+ cell tumors. Beijing: Tongfang Knowledge Network (Beijing) Technology Co., Ltd.; 2020. https:\/\/doi.org\/10.27157\/d.cnki.ghzku.2019.001822.","DOI":"10.27157\/d.cnki.ghzku.2019.001822"},{"issue":"20","key":"274_CR54","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, Jin L, Xia J, Ma S, Liu Y, Li H, Pan B, Chen W, Fei X, Wang C, Xie X, Yu L, Wang G, Li H, Jing G, Cheng H, Zhu F, Sun H, Sang W, Li D, Li Z, Zheng J, Xu K. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol. 2022;40(20):2246\u201356. https:\/\/doi.org\/10.1200\/JCO.21.01676.","journal-title":"J Clin Oncol."},{"key":"274_CR55","doi-asserted-by":"publisher","first-page":"942796","DOI":"10.3389\/fimmu.2022.942796","volume":"13","author":"YA Wang","year":"2022","unstructured":"Wang YA, Dong C, Han YD, Gu ZF, Sun C. Immunosenescence, aging and successful aging. Front Immunol. 2022;13:942796. https:\/\/doi.org\/10.3389\/fimmu.2022.942796.","journal-title":"Front Immunol"},{"issue":"9","key":"274_CR56","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, Yang Q, Nie J, Tang N, Zhang X, Cheng C, Shen L, He J, Ye X, Cao W, Wang H, Han W. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188\u201398. https:\/\/doi.org\/10.1038\/s41423-021-00749-x. Epub 2021 Aug 11.","journal-title":"Cell Mol Immunol."},{"key":"274_CR57","doi-asserted-by":"publisher","first-page":"786046","DOI":"10.3389\/fimmu.2021.786046","volume":"12","author":"SK Wong","year":"2021","unstructured":"Wong SK, Nebhan CA, Johnson DB. Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy. Front Immunol. 2021;12:786046. https:\/\/doi.org\/10.3389\/fimmu.2021.786046.","journal-title":"Front Immunol"},{"key":"274_CR58","doi-asserted-by":"publisher","unstructured":"Xia J, Xu K. GPRC5D CAR-T cell therapy for relapsed\/refractory multiple myeloma: a single-arm phase II clinical trial. Beijing: Tongfang Knowledge Network (Beijing) Technology Co., Ltd.; 2023. https:\/\/doi.org\/10.13201\/j.issn.1004-2806.2023.07.005.","DOI":"10.13201\/j.issn.1004-2806.2023.07.005"},{"key":"274_CR59","doi-asserted-by":"publisher","unstructured":"Xue Y. Clinical study on the safety and efficacy of CD19 CAR-T cell targeted immunotherapy for relapsed\/refractory diffuse large B-cell lymphoma - a single-center, single-arm, open-label clinical study. Beijing: Tongfang Knowledge Network (Beijing) Technology Co., Ltd.; 2023. https:\/\/doi.org\/10.27003\/d.cnki.gojyu.2021.001028.","DOI":"10.27003\/d.cnki.gojyu.2021.001028"},{"issue":"7","key":"274_CR60","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang J, He J, Zhang X, Li J, Wang Z, Zhang Y, Qiu L, Wu Q, Sun Z, Ye X, Yin W, Cao W, Shen L, Sersch M, Lu P. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer J. 2022;12(7):104. https:\/\/doi.org\/10.1038\/s41408-022-00694-6.","journal-title":"Blood Cancer J."},{"issue":"8","key":"274_CR61","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/pharmaceutics14081630","volume":"14","author":"M Yang","year":"2022","unstructured":"Yang M, Olaoba OT, Zhang CY, Kimchi ET, Staveley-O\u2019Carroll KF, Li GF. Cancer immunotherapy and delivery system: an update. Pharmaceutics. 2022;14(8):1630. https:\/\/doi.org\/10.3390\/pharmaceutics14081630.","journal-title":"Pharmaceutics"},{"issue":"10","key":"274_CR62","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1038\/s41423-021-00749-x","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019;6(10):e521\u20139. https:\/\/doi.org\/10.1016\/S2352-3026(19)30115-2.","journal-title":"Lancet Haematol."},{"key":"274_CR63","doi-asserted-by":"publisher","unstructured":"Yan ZX, et al. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma. Abstr\u00a0Clin Cancer Res. 2019;25(23):6995\u20137003. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0101.","DOI":"10.1158\/1078-0432.CCR-19-0101"},{"issue":"13","key":"274_CR64","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","volume":"27","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wang P, Li Z, He Y, Gan W, Jiang H. Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed\/Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2021;27(13):3549\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4543. Epub 2021 Apr 8.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"274_CR65","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"YY Zhang","year":"2020","unstructured":"Zhang YY, Zhang ZM. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321. https:\/\/doi.org\/10.1038\/s41423-020-0488-6.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"274_CR66","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"WH Zhao","year":"2022","unstructured":"Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, Jin SW, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Zhang H, Bai J, Xu Y, Zhu H, Du J, Jiang H, Fan XH, Li JY, Hou J, Chen Z, Zhang WG, Mi JQ, Chen SJ, He AL. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15(1):86. https:\/\/doi.org\/10.1186\/s13045-022-01301-8.","journal-title":"J Hematol Oncol."}],"container-title":["Biological Procedures Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12575-025-00274-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12575-025-00274-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12575-025-00274-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:02:44Z","timestamp":1747731764000},"score":1,"resource":{"primary":{"URL":"https:\/\/biologicalproceduresonline.biomedcentral.com\/articles\/10.1186\/s12575-025-00274-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1186\/s12575-025-00274-5","relation":{},"ISSN":["1480-9222"],"issn-type":[{"value":"1480-9222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not cover animal or human testing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}